Pricing Log in Create free account

MoonLake Immunotherapeutics (MLTX) vs Pharming Group N.V. Sponsored ADR (PHAR)

MoonLake Immunotherapeutics and Pharming Group N.V. Sponsored ADR are both Biotechnology companies. MoonLake Immunotherapeutics and Pharming Group N.V. Sponsored ADR are of similar size ($919.2M and $870.6M). MoonLake Immunotherapeutics has negative trailing earnings, so its P/E is not meaningful; Pharming Group N.V. Sponsored ADR trades at 34.2×. Pharming Group N.V. Sponsored ADR has the higher net margin (6.27% vs 0.00%) and the higher return on invested capital (10.1% vs 0.00%). Across the 15 metrics below, Pharming Group N.V. Sponsored ADR leads on 11 and MoonLake Immunotherapeutics on 4.

Valuation

Metric MLTX PHAR Biotechnology median
P/E n/m 34.22 10.60
P/S n/m 2.23 9.40
P/B 1.98 2.96 2.13
Price to free cash flow n/m 25.00 25.18
EV/EBITDA n/m 17.39 0.66
EV/Sales n/m 2.00 9.02
Earnings yield (33.42%) 2.92% (32.88%)
Free cash flow yield (26.52%) 4.00% (23.13%)

Profitability

Metric MLTX PHAR Biotechnology median
Gross margin 0.00% 85.10% 68.51%
Operating margin 0.00% 8.40% 0.00%
Net margin 0.00% 6.27% 0.00%
Free cash flow margin 0.00% 8.92% 0.00%
Return on equity (67.08%) 8.73% (51.96%)
Return on assets (51.00%) 5.00% (46.06%)
Return on invested capital 0.00% 10.07% 0.00%

Growth

Metric MLTX PHAR Biotechnology median
Revenue growth (TTM) — 6.76% 6.76%
EPS growth (last fiscal year) (86.77%) 125.00% 29.88%
Revenue growth, 5-year CAGR — 12.13% 9.75%
Net income growth, 5-year CAGR 0.00% (40.35%) 0.00%

Health

Metric MLTX PHAR Biotechnology median
Debt to equity 0.23 0.34 0.00
Current ratio 12.56 3.23 4.97
Net debt to EBITDA 1.32 (2.21) 1.01

Dividend

Metric MLTX PHAR Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric MLTX PHAR Biotechnology median
Market cap 919.15m 870.59m 161.82m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack